Why Eli Lilly Stock Climbed to a Record High Today
Key Points
Eli Lilly's shareholders are in store for even more gains, according to a respected investment bank.
The drugmaker is poised to profit from the rapid growth of the global obesity treatment market.
- 10 stocks we like better than Eli Lilly ›
Shares of Eli Lilly (NYSE: LLY) rose to a new all-time high on Tuesday, following upbeat analyst remarks.
Image source: Getty Images.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Getting more bullish
JPMorgan analyst Chris Schott reiterated his overweight (read: buy) rating on Eli Lilly's stock and boosted his share price target from $1,300 to $1,400.
Even after today's gains, JPMorgan's new price forecast implies potential returns of over 13% for investors who buy Eli Lilly's shares now.
The healthcare titan's market capitalization has ballooned to more than $1.1 trillion, driven by the blockbuster success of its popular GLP-1 drugs, Mounjaro and Zepbound.
Schott predicts that the rapid expansion of the U.S. weight-loss drug market and strong growth in international markets will drive Eli Lilly's sales and profits sharply higher.
In turn, Schott expects the medicine maker's earnings to exceed consensus estimates when it reports its second-quarter financial results on Aug. 5.
Additional growth catalysts
The obesity drug market is set to grow even larger. On July 1, the new GLP-1 Bridge program made Zepbound and Foundayo available to eligible Medicare patients for as low as $50 per month.
With an estimated 20 million Medicare patients potentially meeting the criteria for obesity drugs, there's a good chance JPMorgan's $1,400 target price for Eli Lilly's shares proves conservative.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,200,223!*
Now, it’s worth noting Stock Advisor’s total average return is 916% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of July 7, 2026.
JPMorgan Chase is an advertising partner of Motley Fool Money. Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and JPMorgan Chase. The Motley Fool has a disclosure policy.
Recommended Articles
